US · XGN · MEDICAL - DIAGNOSTICS & RESEARCH
Exagen Inc. (XGN) intrinsic value and stock valuation
$3.61as of 2026-11-21 · Mkt cap 160.66M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Exagen Inc. DCF and intrinsic value
InvestorsCraft values XGN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from XGN’s statements →
Exagen Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $66.6M | $55.6M | $52.6M | $45.6M | $48.3M |
| Operating income | -$-14.07M | -$-13.64M | -$-22.84M | -$-46.05M | -$-24.07M |
| Net income | -$-19.95M | -$-15.12M | -$-23.69M | -$-47.39M | -$-26.85M |
| EPSd | -$-925.32K | -$-830.77K | -$-1.34M | -$-2.77M | -$-1.68M |
| Operating cash flow | -$-13.62M | -$-13.28M | -$-14.46M | -$-32.14M | -$-20.27M |
| Capital expenditure | -$-640K | -$-520K | -$-830K | -$-4.32M | -$-2.37M |
| Free cash flow | -$-14.27M | -$-13.79M | -$-15.29M | -$-36.46M | -$-22.64M |
| Total assets | $58M | $44.7M | $56.9M | $86.2M | $123.4M |
| Total debt | $25.7M | $23.2M | $23.2M | $35.2M | $28.1M |
| Net debt | -$-6.51M | $1.17M | -$-13.26M | -$-27.19M | -$-71.38M |
| Total equity | $17.5M | $9.54M | $22.7M | $42.5M | $84.9M |
| Cash and short-term investments | $32.2M | $22M | $36.5M | $62.4M | $99.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $66.6M | $55.6M | $52.6M | $45.6M | $48.3M |
| Cost of revenue | $27.8M | $22.5M | $23.1M | $24.2M | $20.6M |
| Gross profit | $38.8M | $33.1M | $29.5M | $21.4M | $27.7M |
| Research and development expenses | $6.25M | $5.38M | $4.87M | $9.88M | $7.24M |
| Selling, general and administrative expenses | $46.6M | $41.4M | $47.4M | $52M | $44.5M |
| Other expenses | $0.00 | $0.00 | $0.00 | $5.51M | $0.00 |
| Operating expenses | $52.9M | $46.8M | $52.3M | $67.4M | $51.8M |
| Cost and expenses | $80.6M | $69.3M | $75.4M | $91.6M | $72.4M |
| Interest income | $290K | $770K | $1.52M | $830K | $20K |
| Interest expense | $4.32M | $2.23M | $2.33M | $2.45M | $2.62M |
| Depreciation and amortization | $2.12M | $1.72M | $2.17M | $1.56M | $950K |
| Ebitda | -$-13.46M | -$-11.14M | -$-19.15M | -$-43.66M | -$-23.1M |
| Operating income | -$-14.07M | -$-13.64M | -$-22.84M | -$-46.05M | -$-24.07M |
| Total other income/expenses, net | -$-5.83M | -$-1.47M | -$-820K | -$-1.62M | -$-2.61M |
| Income before tax | -$-19.9M | -$-15.1M | -$-23.66M | -$-47.67M | -$-26.68M |
| Income tax expense | $50K | $10K | $30K | -$-280K | $170K |
| Net income | -$-19.95M | -$-15.12M | -$-23.69M | -$-47.39M | -$-26.85M |
| Weighted average shares outstanding | $21.6M | $18.2M | $17.7M | $17.1M | $16M |
| Weighted average diluted shares outstanding | $21.6M | $18.2M | $17.7M | $17.1M | $16M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $32.2M | $22M | $36.5M | $62.4M | $99.4M |
| Net receivables | $10.9M | $7.83M | $6.55M | $6.08M | $9.65M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $48.9M | $36.5M | $47.8M | $72.6M | $112.7M |
| Property, plant and equipment, net | $8.37M | $7.68M | $8.49M | $13.1M | $4.77M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $5.51M |
| Long-term investments | $200K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $9.13M | $8.23M | $9.1M | $13.6M | $10.7M |
| Total assets | $58M | $44.7M | $56.9M | $86.2M | $123.4M |
| Accounts payable | $4.15M | $4.14M | $3.13M | $3.05M | $2.49M |
| Short-term debt | $3M | $1.72M | $1.24M | $1.93M | $590K |
| Deferred revenue | $680K | $730K | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $14.2M | $13.5M | $11.9M | $9.62M | $9.32M |
| Long-term debt | $22.7M | $21.5M | $22M | $33.3M | $27.5M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $26.4M | $21.6M | $22.4M | $34.1M | $29.2M |
| Capital lease obligations | $2.8M | $2.96M | $3.74M | $6.23M | $0.00 |
| Total liabilities | $40.6M | $35.2M | $34.3M | $43.8M | $38.5M |
| Common stock | $20K | $20K | $20K | $20K | $20K |
| Retained earnings | -$-314.28M | -$-294.33M | -$-279.22M | -$-255.53M | -$-208.14M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $17.5M | $9.54M | $22.7M | $42.5M | $84.9M |
| Total investments | $200K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $25.7M | $23.2M | $23.2M | $35.2M | $28.1M |
| Net debt | -$-6.51M | $1.17M | -$-13.26M | -$-27.19M | -$-71.38M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-19.95M | -$-15.12M | -$-23.69M | -$-47.39M | -$-26.85M |
| Depreciation and amortization | $2.12M | $1.72M | $2.17M | $1.56M | $950K |
| Stock-based compensation | $2.16M | $1.76M | $3.62M | $4.7M | $4.73M |
| Change in working capital | -$-1.98M | -$-3.08M | $330K | $1.67M | -$-60K |
| Accounts receivable | -$-3.02M | -$-1.28M | -$-470K | $3.58M | -$-740K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $40K | $310K | $70K | $900K | -$-660K |
| Net cash provided by operating activities | -$-13.62M | -$-13.28M | -$-14.46M | -$-32.14M | -$-20.27M |
| Investments in property, plant and equipment | -$-640K | -$-520K | -$-830K | -$-4.32M | -$-2.37M |
| Acquisitions, net | $10K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-630K | -$-520K | -$-800K | -$-4.32M | -$-2.42M |
| Common stock issued | $22.4M | $200K | $310K | $450K | $69.1M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $24.4M | -$-660K | -$-10.63M | -$-490K | $64.7M |
| Net change in cash | $10.2M | -$-14.46M | -$-25.9M | -$-36.95M | $42M |
| Cash at end of period | $32.4M | $22.2M | $36.7M | $62.6M | $99.5M |
| Operating cash flow | -$-13.62M | -$-13.28M | -$-14.46M | -$-32.14M | -$-20.27M |
| Capital expenditure | -$-640K | -$-520K | -$-830K | -$-4.32M | -$-2.37M |
| Free cash flow | -$-14.27M | -$-13.79M | -$-15.29M | -$-36.46M | -$-22.64M |
Line items
Line items
Line items
About Exagen Inc.
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
- CEO
- John Aballi
- Employees
- 216
- Beta
- 2.02
Explore
Frequently asked questions
What is the intrinsic value of Exagen Inc. (XGN)?
Exagen Inc. (XGN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is XGN undervalued?
XGN trades at a price of $3.61 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.